Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2026)

Indivior Pharmaceuticals has reported Other Accumulated Expenses over the past 4 years, most recently at $14.0 million for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 366.67% year-over-year to $14.0 million; the TTM value through Mar 2026 reached $14.0 million, up 366.67%, while the annual FY2025 figure was $42.0 million, 57.58% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $14.0 million at Indivior Pharmaceuticals, down from $42.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $492.0 million in Q4 2023 and troughed at $3.0 million in Q1 2025.
  • A 4-year average of $123.0 million and a median of $99.0 million in 2024 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 79.88% in 2024 and later skyrocketed 366.67% in 2026.
  • Year by year, Other Accumulated Expenses stood at $492.0 million in 2023, then crashed by 79.88% to $99.0 million in 2024, then tumbled by 57.58% to $42.0 million in 2025, then plummeted by 66.67% to $14.0 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for INDV at $14.0 million in Q1 2026, $42.0 million in Q4 2025, and $106.0 million in Q3 2025.